Bearbmagovva

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is based on the methodology used by Tjalma and c...

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkkit:	Steven Simoens (Dahkki), Arnold G. Vulto (Dahkki), Pieter Dylst (Dahkki)
Materiálatiipa:	Girji
Almmustuhtton:	MDPI AG, 2021-05-01T00:00:00Z.
Fáttát:	article
Liŋkkat:	Connect to this object online.
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
Dahkki: Alina Uifălean, et al.
Almmustuhtton: (2018)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
Dahkki: Yannick Vandenplas, et al.
Almmustuhtton: (2022)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
Dahkki: Jiangping Yang, et al.
Almmustuhtton: (2022)

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
Dahkki: Liese Barbier, et al.
Almmustuhtton: (2021)

A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients
Dahkki: Reza Safaei Nodehi, et al.
Almmustuhtton: (2022)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
Dahkki: Anne Julienne Genuino, et al.
Almmustuhtton: (2019)

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets
Dahkki: Philip Lammers, et al.
Almmustuhtton: (2014)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
Dahkki: Michela Piezzo, et al.
Almmustuhtton: (2021)

Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023
Dahkki: Qiyou Wu, et al.
Almmustuhtton: (2024)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
Dahkki: Sadeghi S, et al.
Almmustuhtton: (2014)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
Dahkki: Liese Barbier, et al.
Almmustuhtton: (2022)

Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah ... [et al.]
Dahkki: Hasbullah, Harissa H, et al.
Almmustuhtton: (2018)

Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report
Dahkki: Peter G. Rose
Almmustuhtton: (2023)

Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier
Dahkki: Brandon M. Bordeau, et al.
Almmustuhtton: (2022)

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
Dahkki: Azadeh Moghaddas, et al.
Almmustuhtton: (2016)

Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study
Dahkki: María Reyes Abad-Sazatornil, et al.
Almmustuhtton: (2021)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
Dahkki: Yannick Vandenplas, et al.
Almmustuhtton: (2021)

Combined trastuzumab and radiation therapy for HER2-positive uterine serous carcinoma: A case report
Dahkki: SPH Mao, et al.
Almmustuhtton: (2023)

Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression
Dahkki: Christina Vasalou, et al.
Almmustuhtton: (2024)

Adverse reactions for the use of the monoclonal trastuzumab antibody in the treatment of patients with HER2 positive breast cancer
Dahkki: Iago Dilion Lima Cavalcanti, et al.

Economic evaluation of biosimilars for reimbursement purposes - what, when, how?
Dahkki: Evelien Moorkens, et al.
Almmustuhtton: (2020)

Focused physicochemical stability study of reconstituted trastuzumab biosimilar SB3 (Ontruzant®) stored in the original vials over 28 days
Dahkki: Knoll Laura, et al.
Almmustuhtton: (2024)

A rapid method for relative quantification of N-glycans from a therapeutic monoclonal antibody during trastuzumab biosimilar development
Dahkki: Zaneer Segu, et al.
Almmustuhtton: (2020)

An unexpected and severe infusion reaction induced by trastuzumab
Dahkki: M.ª Sacramento Díaz-Carrasco, et al.
Almmustuhtton: (2014)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
Dahkki: Teresa Barcina Lacosta, et al.
Almmustuhtton: (2022)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
Dahkki: Silvia Pelligra, et al.
Almmustuhtton: (2020)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
Dahkki: K. R. Zeinalova, et al.
Almmustuhtton: (2014)

Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review
Dahkki: I. V. Kolyadina
Almmustuhtton: (2023)

Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
Dahkki: Che YQ, et al.
Almmustuhtton: (2019)

An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases
Dahkki: A. S. Kolbin, et al.
Almmustuhtton: (2019)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
Dahkki: Elif Car, et al.
Almmustuhtton: (2023)

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
Dahkki: Yannick Vandenplas, et al.
Almmustuhtton: (2021)

Trastuzumab-Docetaxel combination chemotherapy induced severe onychopathy
Dahkki: Sidharth Sonthalia, et al.
Almmustuhtton: (2017)

Trastuzumab-Induced Organising Pneumonia in Breast Cancer Patient
Dahkki: Sapna Dixit, et al.
Almmustuhtton: (2024)

Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
Dahkki: Chen Y, et al.
Almmustuhtton: (2024)

Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft
Dahkki: Zhang Anli, et al.
Almmustuhtton: (2010)

Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC
Dahkki: Feifei Li, et al.
Almmustuhtton: (2024)

Osthole Synergizes With HER2 Inhibitor, Trastuzumab in HER2-Overexpressed N87 Gastric Cancer by Inducing Apoptosis and Inhibition of AKT-MAPK Pathway
Dahkki: Yun Yang, et al.
Almmustuhtton: (2018)

Generic Medicine Pricing Policies in Europe: Current Status and Impact
Dahkki: Pieter Dylst, et al.
Almmustuhtton: (2010)

How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing?
Dahkki: Dylst P, et al.
Almmustuhtton: (2012)